Labcorp’s second quarter results were well received by the market, as the company delivered solid revenue growth and exceeded Wall Street’s non-GAAP profit expectations. Management attributed the quarter’s performance to continued momentum in specialty testing, strong execution in its Diagnostics and Biopharma Laboratory Services segments, and expanding partnerships with health systems. CEO Adam Schechter highlighted that double-digit growth in specialty areas such as oncology and neurology, along with the nationwide launch of new tests like ColoSense, contributed meaningfully to the quarter. The company also noted progress in consumer-initiated testing, supported by digital innovations and expanded payer coverage.
Is now the time to buy LH? Find out in our full research report (it’s free for active Edge members).
Labcorp (LH) Q2 CY2026 Highlights:
- Revenue: $3.73 billion vs analyst estimates of $3.71 billion (5.8% year-on-year growth, in line)
- Adjusted EPS: $4.99 vs analyst estimates of $4.77 (4.6% beat)
- The company slightly lifted its revenue guidance for the full year to $14.77 billion at the midpoint from $14.73 billion
- Management raised its full-year Adjusted EPS guidance to $18.33 at the midpoint, a 1.7% increase
- Operating Margin: 12.1%, in line with the same quarter last year
- Organic Revenue rose 4.2% year on year (beat)
- Market Capitalization: $25.4 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Labcorp’s Q2 Earnings Call
- Lisa Gill (JPMorgan): asked about the sustainability of organic volume growth and potential headwinds from ACA and Medicaid changes. CEO Adam Schechter explained that specialty testing and new partnerships are driving volumes, while CFO Julia Wang confirmed the company’s ACA impact assumptions remain unchanged in guidance.
- Kevin Caliendo (UBS): inquired about volume reporting and performance versus the broader market. Schechter noted the company is outpacing market growth due to hospital and regional lab partnerships, and Wang clarified that test-per-accession growth supports price mix improvements.
- Elizabeth Anderson (Evercore ISI): sought details on the Biopharma Laboratory Services segment, focusing on the impact of restructuring versus end-market improvement. Schechter highlighted Central Labs’ strength and explained that Early Development benefits from completed strategic actions and better study starts.
- Jack Meehan (Operon Research): asked about the delta in diagnostic lab organic growth versus peers and margin implications. Schechter responded that Labcorp prioritizes high-margin specialty areas over lower-margin partnerships, while Wang emphasized consistent margin expansion across segments.
- David Westenberg (Piper Sandler): questioned the long-term impact of self-collection and at-home testing on industry economics. Schechter said self-collection will complement, not replace, traditional phlebotomy, with the mix depending on patient needs and test complexity.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will be monitoring (1) the scale and adoption of new specialty and consumer tests like ColoSense, (2) continued margin improvement from strategic actions in Early Development and efficiency initiatives under Launchpad, and (3) the progression of major health system partnerships and acquisitions. Developments around regulatory changes, especially PAMA and ACA, will also be closely watched for potential impact on Labcorp’s payer mix and revenue stability.
Labcorp currently trades at $314.02, up from $307.15 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
